Writing the Specifications for NHIRD Research. Tzeng-Ji Chen

Size: px
Start display at page:

Download "Writing the Specifications for NHIRD Research. Tzeng-Ji Chen"

Transcription

1 Writing the Specifications for NHIRD Research Tzeng-Ji Chen

2 From Internet * including 答應來演講?!

3 My Sweet Home

4 3 Months after Furnishing Lesson: Specs do matter.

5 From Internet

6 Key Concepts

7 Paper Production Flow Atmosphere Idea Method Writing Journal Materials Computing Statistics English Teams Tools Infrastructure

8 1. 資料擷取 2. 資料處理 3. 統計分析 Courtesy of Yu-Chun Chen

9 PR time ( )

10 PR time ( )

11 GDP (Good Data Processing) Protocol Diary Script comments Avoid fancy or illegible writing Programming style

12

13

14 File Structure of NHIRD Datasets to Process Single file Multiple files: Of the same format Of similar formats in different years Of different formats, but connected through Primary key / foreign key Loop-up table

15 15

16

17

18 Main Frame of Processing

19 Setting the Goal Quantity One is enough More papers, more better Quality trade-off Fulfilling the minimum requirement High-impact Willingness to pay (for NHIRD datasets) Willingness to devote (time and effort)

20 Writing the Specs for NHIRD Research Decide on the selection of datasets Complete datasets Datasets sampled by visit (OPD + ER: 1/500; Adm.: 1/20) Datasets sampled by person (1 million cohort: old vs. new) Time frame Connected and ancillary datasets Decide on the selection of fields Decide on the processing of fields Define the major events Elaborate the processing workflow interactive, reiterative, collaborative process Decide on the structure and format of output table(s)

21 Real-Life Examples

22 1. Trazodone as poor men's Viagra: a prescription database analysis among urological practice in Taiwan

23 Source of Idea:

24 J Urol 2003;169:

25 J Urol 2003;169:

26 J Urol 2003;169:

27 Datasets (1/3) Ambulatory sector Datasets sampled by visit (=> utilization amount)? Datasets sampled by person (=> prevalence)? Complete datasets (=> $$$) X

28 Datasets (2/3) CD: ambulatory care expenditures by visits (visit file): , OO: details of ambulatory care orders (order file): ,

29 DRUG 藥品主檔 29

30 Datasets (3/3) HOSB: registry for contracted medical facilities? PER: registry for medical personnel? DOC: registry for board-certified specialists? DRUG: registry for drug prescriptions? ID: registry for beneficiaries => + Complete!

31 Fields OO DRUG_NO CD ID, ID_BIRTHDAY, ID_SEX ACODE_ICD9_1, ACODE_ICD9_2, ACODE_ICD9_3 FUNC_DATE FUNC_TYPE, PRSN_ID, HOSP_ID HOSB HOSP_CONT_TYPE, AREA_NO_H ID ID, INS_ID, INS_ID_TYPE, INS_AMT, ID_IN_DATE, ID_OUT_DATE

32 Field Processing Patient s age and age group Age = (FUNC_DATE - ID_BIRTHDAY) in Y? Age = FUNC_DATE in Y - ID_BIRTHDAY in Y? <=39, 40-59, >=60? Diagnosis group Major Dx field? All 3 Dx fields? All Dx groups? ICD-9-CM s first 3 digits CCS single level Target Dx group(s)? (y/n) Visit-based? Person-based? Exclusivity? Non-exclusivity? Hierarchy?

33 Major Event (DRUG_NO) Trazodone (ATC: N06AX05) A A A A A A A A A A A B B B A

34 Data Processing (1/5) Extract records from OO according to DRUG_NO (=> OO_Trazodone_?.txt) Extract records from CD according to PK (FEE_YM + APPL_TYPE + HOSP_ID + APPL_DATE + CASE_TYPE + SEQ_NO) in OO (=> CD_Trazodone_?.txt) Extract records from CD_Trazodone_?.txt according to FUNC_TYPE = 08 (=> CD_Trazodone_?_GU.txt) Extract records from OO_Trazodone_?.txt according to PK in CD_Trazodone_?_GU.txt (=> OO_Trazodone_?_GU.txt) For both S_{CD,OO}{ } and LHID2000 s R{01..20}_{CD,OO}{ } Further processing

35 Trazodone Rx in S_{CD,OO} (1:500) Year No. of Visits with Trazodone No. of GU Visits with Trazodone F + M + U F M F + M + U F M , , , , , , ,164 1,095 1, ,087 1, ,181 1,160 1, ,305 1,265 1, ,358 1,338 1,

36 Data Processing (2/5) For LHID2000 : limited to male patients User in each year Based on FUNC_DATE New user in each year No GU visit with Trazodone Rx in any of previous years Denominator in each year Based on R{01..20}_ID{ } Judged according to ID_IN_DATE and ID_OUT_DATE : ( ID_IN_DATE <= target year ) AND ( ( ID_OUT_DATE = blank ) OR ( ID_OUT_DATE >= target year ) )

37 Trazodone Rx at GU Visits in LHID2000 Year No. of Pat. / No. of New Pat. No. of Male Beneficiaries 0-39 y y 60+ y 0-39 y y 60+ y / / / ,737 99,731 55, / / / , ,946 57, / / / , ,035 58, / / / , ,633 59, / / / , ,791 60, / / / , ,365 61, / / / , ,445 62, / / / , ,940 62, / / / , ,354 63, / / / , ,346 64, / / / , ,060 65, / / / , ,526 66,935

38 Data Processing (3/5) No. of GU visits with Trazodone Rx by a patient between 1997 and 2008 Frequency distribution stratified by patient s age Age : age at the first visit

39

40 Data Processing (4/5) Distribution of diagnoses among GU visits with Trazodone by visit by patient Diagnosis groups (after observing the preliminary Dx distrib.) Impotence : Impotence of organic origin : Psychosexual dysfunction : Unspecified psychosexual disorder Depression 296 : Affective psychoses 300 : Neurotic disorders 311 : Depressive disorder, not elsewhere classified Impotence + Depression

41 impotence depression Visit-based (n = 18,052) 9,002 (49.9%) 1,141 (6.3%) 986 (5.5%) 6,923 (38.4%) impotence depression Pat.-based (n = 4,676) 2,596 (55.5%) 407 (8.7%) 242 (5.2%) 1,431 (30.6%)

42 Data Processing (5/5) Distribution of highest monthly insured income ( insured payroll-related amount ) in patients having GU visits for Trazodone in general population (cohort) excluding patients with Trazodone at GU Highest monthly insured income of a patient between 1997 and 2008 INS_AMT : monthly insured income of type 1-3 of the insured Cave : INS_ID_TYPE = 4 OR 5 after 2006 In an ID record of those insured dependently Income = INS_IDs highest monthly insured income * One can have several INS_IDs. Minimal monthly insured income : arbitrarily set to 14,400

43 Median (IQR) : 33,300 (27,200) (n = 4,676) Median (IQR) : 31,800 (24,800) (n = 499,798) * Wilcoxon rank sum test with continuity correction : p =

44 2. Venous thromboembolism (VTE) among cancer patients in Taiwan

45 Datasets Datasets on special request All claims belonging to cancer patients according to HV registry datasets, > 100 GB ID registry Whole population 43 datasets, 22.6 GB

46 Cancer Patients Patients hospitalized with cancer diagnosis ( ) from (DD) (follow up until 2006) Excluding those who had cancer diagnosis in 1996, either at OPD or at hospitalization

47 VTE Events Hospitalization with VTE diagnosis Pulmonary embolism: DVT: Use of anticoagulants during the hospitalization with VTE diagnosis B01AA: Vitamin K antagonists B01AB: Heparin group (total dose >= 5 KIU / Adm.) VTE Dx AND ( (B01AA [Y]) OR (B01AB [dosage]) )

48 Output Table (1/6) One cancer patient one record 1. ID 2. Date of first cancer diagnosis The IN_DATE of the first hospitalization with cancer diagnosis 3. Birthday 4. Sex

49 Output Table (2/6) 5. Type of first cancer (2 fields) Use original ICD9CM code for cancer Concomitant cancer ICD code => Do not record Type of other cancers than first cancer (judged according to first 3 digits) (5 pairs [dx + IN_DATE]) (in hospitalization records) (only from the records with discharge) (after the time of first cancer diagnosis : IN_DATE of the record > OUT_DATE of first cancer diagnosis)

50 Output Table (3/6) 7. Co-morbidities (in both ambulatory and hospitalization records) (before or at the time of first cancer diagnosis) (consider all existing diagnoses except CM10) CM1: Hypertension ( ): 1 or 0 CM2: DM (250): 1 or 0 CM3: Congestive heart failure (428): 1 or 0 CM4: Ischemic heart disease ( ): 1 or 0 CM5: Renal diseases ( ): 1 or 0 CM6: Liver diseases ( ): 1 or 0

51 Output Table (4/6) 7. Co-morbidities (in both ambulatory and hospitalization records) (before or at the time of first cancer diagnosis) (consider all appearing diagnoses except CM10) CM7: Cerebrovascular disease ( ): 1 or 0 CM8: COPD ( ): 1 or 0 CM9: Hyperlipidemia (272): 1 or 0 CM10: History of VTE (415.1, , before the index hospitalization with cancer diagnosis): 1 or 0 (in hospitalization records) (before the time of first cancer diagnosis)

52 Output Table (5/6) 8. Type of the first VTE event (in hospitalization records) (after or at the time of first cancer diagnosis) No VTE: 0 PE (415.1): 1 DVT ( ): 2 PE + DVT ( ): 3 9. Date of the first VTE event The IN_DATE of the index hospitalization with VTE diagnosis and treatment No VTE: blank

53 Output Table (6/6) 10. Type of death No death / unknown: 0 In-hospital death: 1 Assumed death: 2 (drop-out from NHI within 30 days after the last hospitalization with AAD) 11. Date of last follow-up (OPD or hospitalization or drop-out from NHI) (in living patients), in-hospital death or assumed death

54 Data Processing (1/5) Cancer.plx => Cancer.txt [ PatID, InDate, OutDate, Birthday, Sex, Dx1, Dx2 ] the first admission with cancer diagnosis admission date between 1997 and 2005 because of cancer as one of diagnoses ( ) no cancer diagnosis in 1996, either at OPD or at hospitalizations

55 Data Processing (2/5) VTE_All.plx => VTE_All_DD_ txt, VTE_All_DD_ txt, VTE_All_DO_ txt all admissions with VTE diagnosis not limited to defined cancer patients

56 Data Processing (3/5) VTE.plx => VTE.txt [ PatID, VTEInDate, VTEType ] all admissions with VTE and drug treatment non-heparin (NON_HEPARIN.txt) => VTE heparin (HEPARIN_KIU.txt [ heparin, dosage in KIU ]) dosage >= 5 KIU => VTE not limited to defined cancer patients VTE type : 0 (no), 1 (PE, 415.1), 2 (DVT, ), 3 (PE + DVT)

57 Data Processing (4/5) Death.plx => Death.txt [ PatID, DeathType, LastFUDate ] not limited to defined cancer patients death type : 0 (no), 1 (in-hospital death), 2 (assumed death)

58 Data Processing (5/5) Final.plx (combine Cancer.txt, VTE.txt, Death.txt) => Final.txt [ PatID, InDate, Birthday, Sex, Dx1, Dx2, ExtraCa1, ExtraDate1, ExtraCa2, ExtraDate2, ExtraCa3, ExtraDate3, ExtraCa4, ExtraDate4, ExtraCa5, ExtraDate5, CM1, CM2, CM3, CM4, CM5, CM6, CM7, CM8, CM9, CM10, VTEType, VTEInDate, DeathType, LastFUDate ]

59 Tips in Data Processing (1/2) VTE.txt [ PatID, VTEInDate, VTEType ] B01AA + B01AB : 48 available drug items + 28 old items Heparin s total dosage in a combined full admission (fragmented claims) : based on ID + IN_DATE In all admissions with VTE Dx (not limited to defined cancer patients) with non-heparin : 15,299 admission records with heparin >= 5 KIU / admission record : 8,191 admission records with heparin >= 10 KIU / admission record : 6,988 admission records with heparin >= 25 KIU / admission record : 6,394 admission records with non-heparin or heparin : 18,532 admission records with non-heparin or heparin >= 5 KIU / admission record : 18,120 admission records with non-heparin or heparin >= 10 KIU / admission record : 17,576 admission records with non-heparin or heparin >= 25 KIU / admission record : 17,364 admission records

60 Tips in Data Processing (2/2) Death.txt [ PatID, DeathType, LastFUDate ] Last date of medical care use Last date of hospitalizations (OUT_DATE of the last hospitalization) Last date of ambulatory visits (FUNC_DATE of the last visit) Last date of hospitalization with AAD (discharge against [medical] advice) Last date of entry into insurance Last date of cancellation of insurance ID (?) (=> => ) Patients with in-hospital death : Last date of hospitalization AAD with assumed death : cancellation of insurance within 30 days after the last date of hospitalizations with AAD, and no more entry into insurance Others (living or death unknown) : last date of medical care use as LastFUDate

61 Output 497,185 records into Microsoft Access

62 I have a dream

63 The NHIRD research will enable the current generation of medical professionals in Taiwan to know the Amis better than the Amish. * Amis : 阿美族

64 NHIRD (GPRD) (NAMCS)

65 Cum. no. of papers Courtesy of Yu-Chun Chen Year

66 Thanks for Your Attention!

Symptomatic Venous Thromboembolism after Total Hip/Knee Replacement: A Population-based Taiwan Study

Symptomatic Venous Thromboembolism after Total Hip/Knee Replacement: A Population-based Taiwan Study IMPROVING PATIENT SAFETY Preventing & Managing Venous Thromboembolism Session 8 Data Driving Strategies for VTE Prevention and Management 3/30/2012; 15.35-15.55 Symptomatic Venous Thromboembolism after

More information

Wind, Water, Wound, Walk Do the Data Deliver the Dictum?

Wind, Water, Wound, Walk Do the Data Deliver the Dictum? Wind, Water, Wound, Walk Do the Data Deliver the Dictum? Elizabeth M. Sonnenberg, MD, Caroline E. Reinke, MD MSHP, Edmund K. Bartlett, MD, Karole T. Collier, Giorgos C. Karakousis, MD, Daniel N. Holena,

More information

Condition Congestive heart failure I11.0; I13.0; I13.2; I42.0; I50 CO3C Left ventricular dysfunction I50.1; I50.9 E11 1; E11 9

Condition Congestive heart failure I11.0; I13.0; I13.2; I42.0; I50 CO3C Left ventricular dysfunction I50.1; I50.9 E11 1; E11 9 Comparative effectiveness and safety of non-vitamin K antagonists oral anticoagulants (OACs) and warfarin in daily clinical practice: A propensity weighted nationwide cohort study. Supplementary material

More information

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Outcome Measures (Claims Based)

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Outcome Measures (Claims Based) Last Updated: Version 4.3 NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Information Form Collected For: CMS Outcome Measures (Claims Based) Measure Set: CMS Mortality Measures Set

More information

Efficiency Methodology

Efficiency Methodology Efficiency Methodology David C. Schutt, MD Bob Kelley Thomson Healthcare October 2007 Overview Definition Clinical Grouping Methods Implementation Considerations Reporting to Physician Organizations Example

More information

Adrenal Insufficiency in the Elderly: A Nationwide Study of Hospitalizations in Taiwan

Adrenal Insufficiency in the Elderly: A Nationwide Study of Hospitalizations in Taiwan Tohoku J. Exp. Med., 2010, 221, 281-285 Adrenal Insufficiency in the Elderly 281 Adrenal Insufficiency in the Elderly: A Nationwide Study of Hospitalizations in Taiwan Yi-Chun Chen, 1 Yu-Chun Chen, 2 Li-Fang

More information

全民健康保險研究資料庫在急診醫療利用分析之應用

全民健康保險研究資料庫在急診醫療利用分析之應用 全民健康保險研究資料庫開發與應用研討會 全民健康保險研究資料庫在急診醫療利用分析之應用 翁瑞宏 嘉南藥理科技大學醫管系暨碩士班助理教授 黃金安 台中榮民總醫院急診醫學科主任 2009 年 9 月 3 日 Outline Jin-An Huang, Rhay-Hung Weng, Wen-Chen Tsai, Wei-Hsiung Hu and Dar-Yu Yang, Analysis of Emergency

More information

Malignant transformation of oral submucous fibrosis in Taiwan: A nationwide population-based retrospective cohort study

Malignant transformation of oral submucous fibrosis in Taiwan: A nationwide population-based retrospective cohort study Accepted: 9 March 2017 DOI: 10.1111/jop.12570 ORIGINAL ARTICLE Malignant transformation of oral submucous fibrosis in Taiwan: A nationwide population-based retrospective cohort study Po-Yu Yang 1,2 Yi-Tzu

More information

COST-EFFECTIVENESS ANALYSIS OF ORAL CAVITY CANCER IN TAIWAN: A POPULATION-BASED STUDY

COST-EFFECTIVENESS ANALYSIS OF ORAL CAVITY CANCER IN TAIWAN: A POPULATION-BASED STUDY COST-EFFECTIVENESS ANALYSIS OF ORAL CAVITY CANCER IN TAIWAN: A POPULATION-BASED STUDY Hsiang-Tsai Chiang Chun-Yi Tu Lie-Fen Lin Ph.D. Program of Business, Ph.D. Program of Business, Ph.D. Program of Business,

More information

Chapter 3: Morbidity and Mortality in Patients with CKD

Chapter 3: Morbidity and Mortality in Patients with CKD Chapter 3: Morbidity and Mortality in Patients with CKD In this 2017 Annual Data Report (ADR) we introduce analysis of a new dataset. To provide a more comprehensive examination of morbidity patterns,

More information

JAWDA Performance Quarterly KPI Profile (Clinic & Centers) March 2018

JAWDA Performance Quarterly KPI Profile (Clinic & Centers) March 2018 JAWDA Performance KPI Profile (Clinic & Centers) March 2018 1 P a g e Introduction: Physician office, clinic, and healthcare centers provide primary care function including health education, prevention,

More information

Venous Thromboembolism National Hospital Inpatient Quality Measures

Venous Thromboembolism National Hospital Inpatient Quality Measures Venous Thromboembolism National Hospital Inpatient Quality Measures Presentation Overview Review venous thromboembolism as a new mandatory measure set Outline measures with exclusions and documentation

More information

Clinical Safety & Effectiveness Session # 9

Clinical Safety & Effectiveness Session # 9 Clinical Safety & Effectiveness Session # 9 Women s Health Venous Thromboembolism Prophylaxis DATE Educating for Quality Improvement & Patient Safety 1 What We Are Trying to Accomplish? OUR AIM STATEMENT

More information

ASSESSMENT OF EFFECTIVENESS

ASSESSMENT OF EFFECTIVENESS W.M. Glinkowski 1,2,3,A.Górecki 1 WEB BASED DATABASE FOR THE ASSESSMENT OF EFFECTIVENESS OF THROMBOEMBOLIC PROPHYLAXIS IN ORTHOPAEDIC SURGERY. PRELIMINARY STUDY 1 Chair and Department of Orthopaedics and

More information

Chapter 6: Healthcare Expenditures for Persons with CKD

Chapter 6: Healthcare Expenditures for Persons with CKD Chapter 6: Healthcare Expenditures for Persons with CKD In this 2017 Annual Data Report (ADR), we introduce information from the Optum Clinformatics DataMart for persons with Medicare Advantage and commercial

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Dharmarajan K, Wang Y, Lin Z, et al. Association of changing hospital readmission rates with mortality rates after hospital discharge. JAMA. doi:10.1001/jama.2017.8444 etable

More information

SOC s Guide to the 2013 CMS New Core Measures for Stroke

SOC s Guide to the 2013 CMS New Core Measures for Stroke SOC s Guide to the 2013 CMS New Core Measures for Stroke Since 2004, the Centers for Medicare & Medicaid Services (CMS) has collected quality data from acute care hospitals on a voluntary basis under the

More information

Research Article Patterns of Nonemergent Visits to Different Healthcare Facilities on the Same Day: A Nationwide Analysis in Taiwan

Research Article Patterns of Nonemergent Visits to Different Healthcare Facilities on the Same Day: A Nationwide Analysis in Taiwan e Scientific World Journal, Article ID 627580, 8 pages http://dx.doi.org/10.1155/2014/627580 Research Article Patterns of Nonemergent Visits to Different Healthcare Facilities on the Same Day: A Nationwide

More information

SCORES FOR 4 TH QUARTER, RD QUARTER, 2014

SCORES FOR 4 TH QUARTER, RD QUARTER, 2014 SCORES FOR 4 TH QUARTER, 2013 3 RD QUARTER, 2014 PATIENT SATISFACTION SCORES (HCAHPS): 4 STARS OUT OF 5 (ONLY 4 AREA ACUTE CARE HOSPITALS RECEIVED A 4-STAR RATING. NONE ACHIEVED 5-STARS). STRUCTURAL MEASURES:

More information

50198 Federal Register / Vol. 75, No. 157 / Monday, August 16, 2010 / Rules and Regulations

50198 Federal Register / Vol. 75, No. 157 / Monday, August 16, 2010 / Rules and Regulations 50198 Federal Register / Vol. 75, No. 157 / Monday, August 16, 2010 / Rules and Regulations mstockstill on DSKH9S0YB1PROD with RULES2 VerDate Mar2010 17:02 Aug 13, 2010 Jkt 220001 PO 00000 Frm 00158

More information

Registry Highlights. Dale Daniel Symposium Hip Fracture Registry. Overall Volume by Year and Region 3/7/2014

Registry Highlights. Dale Daniel Symposium Hip Fracture Registry. Overall Volume by Year and Region 3/7/2014 Dale Daniel Symposium 2014 Registry Highlights Overview: Updated Volume NCAL/SCAL Snapshot Hip Fracture Registry Update Gary Zohman, MD SCAL Regional Lead Anaheim, CA Quarterly Quality Report Review Future

More information

Zhao Y Y et al. Ann Intern Med 2012;156:

Zhao Y Y et al. Ann Intern Med 2012;156: Zhao Y Y et al. Ann Intern Med 2012;156:560-569 Introduction Fibrates are commonly prescribed to treat dyslipidemia An increase in serum creatinine level after use has been observed in randomized, placebocontrolled

More information

Adjunct Lecturer. National Yang-Ming University, Taiwan. Taipei Veterans General Hospital, Taiwan

Adjunct Lecturer. National Yang-Ming University, Taiwan. Taipei Veterans General Hospital, Taiwan Kuan-Po Peng MD Adjunct Lecturer National Yang-Ming University, Taiwan Taipei Veterans General Hospital, Taiwan Nothing to declare Disclosure Experience from the Taiwan National Health Insurance Research

More information

Determining differences in health care costs before and after Alzheimer s diagnosis using SAS Studio

Determining differences in health care costs before and after Alzheimer s diagnosis using SAS Studio Determining differences in health care costs before and after Alzheimer s diagnosis using SAS Studio ABSTRACT Problem: Delayed or missed diagnoses of Alzheimer s might deprive afflicted individuals of

More information

Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden

Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:

More information

Venous Thromboembolism. Prevention

Venous Thromboembolism. Prevention Venous Thromboembolism Prevention August 2010 Venous Thromboembloism Prevention 1 1 Expected Practice Assess all patients upon admission to the ICU for risk factors of venous thromboembolism (VTE) and

More information

Comprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma

Comprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma Comprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma Pharmacoepidemiology Unit July 10, 2014 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca

More information

Clinical Trend Discovery and Analysis of Taiwanese Health Insurance Claims Data. Divya P. Pillai. S.B., Massachusetts Institute of Technology (2015)

Clinical Trend Discovery and Analysis of Taiwanese Health Insurance Claims Data. Divya P. Pillai. S.B., Massachusetts Institute of Technology (2015) Clinical Trend Discovery and Analysis of Taiwanese Health Insurance Claims Data by Divya P. Pillai S.B., Massachusetts Institute of Technology (2015) Submitted to the Department of Electrical Engineering

More information

Boehringer Ingelheim Page 6 of 178 Study report for non-interventional studies based on existing data BI Study Number

Boehringer Ingelheim Page 6 of 178 Study report for non-interventional studies based on existing data BI Study Number Page 6 of 178 report for non-interventional studies based on existing data BI Number 1160.144 c14462719-01 International GmbH or one or more of its affiliated companies 1. ABSTRACT Title of study: Keywords:

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life

More information

Venous Thromboembolism Prophylaxis

Venous Thromboembolism Prophylaxis Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January

More information

Definitions of chronic conditions used to define the number of serious comorbidities in the study.

Definitions of chronic conditions used to define the number of serious comorbidities in the study. Supplementary Table 1 Definitions of chronic conditions used to define the number of serious comorbidities in the study. Comorbidity ICD-9 Code Description CAD/MI 410.x Acute myocardial infarction 411.x

More information

Table 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings

Table 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings CMS-1345-P 174 Table 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings AIM: Better Care for Individuals 1. Patient/Care Giver Experience

More information

An Analysis of Prescribing of Methylphenidate Hydrochloride in QRESEARCH

An Analysis of Prescribing of Methylphenidate Hydrochloride in QRESEARCH An Analysis of Prescribing of Methylphenidate Hydrochloride in QRESEARCH An analysis using QRESEARCH for the Department of Health Authors: Professor Julia Hippisley-Cox Professor Mike Pringle Ronan Ryan

More information

Site Training. The 39 th Multicenter Airway Research Collaboration (MARC-39) Study

Site Training. The 39 th Multicenter Airway Research Collaboration (MARC-39) Study Site Training The 39 th Multicenter Airway Research Collaboration (MARC-39) Study 1 Study Leadership Kohei Hasegawa, MD, MPH (PI) Carlos Camargo, MD, DrPH (Co-I) Project Coordination: Catalina Gimenez-Zapiola

More information

Unstable INR Has Implications for Healthcare Resource Use. Janssen Pharmaceuticals, Inc.

Unstable INR Has Implications for Healthcare Resource Use. Janssen Pharmaceuticals, Inc. Unstable INR Has Implications for Healthcare Resource Use Janssen Pharmaceuticals, Inc. Stable INR is essential for effective anticoagulation treatment Achieving a stable international normalized ratio

More information

Drug prescriptions (Pharm) Exposure (36/48 months)

Drug prescriptions (Pharm) Exposure (36/48 months) ANNEX SECTION PART A - Study design: Figure 1 overview of the study design Drug prescriptions (Pharm) 2006-2010 Exposure (36/48 months) flexible time windows (e.g. 90 days) time index date (hospital discharge)

More information

PHARMO Database Network

PHARMO Database Network Pros & cons in Oncology studies PHARMO Myrthe Database van Herk-Sukel, Network PhD 1 Disclosure Myrthe van Herk-Sukel is an employee of the PHARMO Institute for Drug Outcomes Research. This independent

More information

EHMRG SCORE STUDY version 6.2; date: 11Jul11 PI: Dr. Douglas Lee. Study Background

EHMRG SCORE STUDY version 6.2; date: 11Jul11 PI: Dr. Douglas Lee. Study Background EHMRG SCORE STUDY version 6.2; date: 11Jul11 PI: Dr. Douglas Lee Study Background Heart failure (HF) is a leading cause of morbidity and cardiovascular mortality. The burden of HF has increased over time

More information

PHPG. Utilization and Expenditure Analysis for Dually Eligible SoonerCare Members with Chronic Conditions

PHPG. Utilization and Expenditure Analysis for Dually Eligible SoonerCare Members with Chronic Conditions PHPG The Pacific Health Policy Group Utilization and Expenditure Analysis for Dually Eligible SoonerCare Members with Chronic Conditions Prepared for: State of Oklahoma Oklahoma Health Care Authority April

More information

pat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16

pat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE

More information

ACO/HCC/Coding Presentation

ACO/HCC/Coding Presentation ACO/HCC/Coding Presentation Prepared by Kristin & Sheree Date 5/15/2013 CMP ACO Background CMP is participating in the Medicare Shared Savings ACO program (Track 1) which is a 3 year agreement With Track

More information

Commercial Health Insurance Claims Data. for Studying HIV/AIDS Care. Senior Scientist, Innovus Epidemiology. David D.

Commercial Health Insurance Claims Data. for Studying HIV/AIDS Care. Senior Scientist, Innovus Epidemiology. David D. Commercial Health Insurance Claims Data for Studying HIV/AIDS Care David D. Dore, PharmD, PhD Senior Scientist, Innovus Epidemiology Adjunct Assistant Professor, Alpert Medical School, Brown University

More information

Surgical Outcomes: A synopsis & commentary on the Cardiac Care Quality Indicators Report. May 2018

Surgical Outcomes: A synopsis & commentary on the Cardiac Care Quality Indicators Report. May 2018 Surgical Outcomes: A synopsis & commentary on the Cardiac Care Quality Indicators Report May 2018 Prepared by the Canadian Cardiovascular Society (CCS)/Canadian Society of Cardiac Surgeons (CSCS) Cardiac

More information

A guide to anticoagulation management and self-testing

A guide to anticoagulation management and self-testing A guide to management and self-testing Understanding If you re reading this, you, or someone you care about, may be on oral therapy, usually treated with a vitamin K antagonist (VKA). VKAs, such as warfarin,

More information

Warfarin & You By V. B. Blake

Warfarin & You By V. B. Blake Warfarin & You By V. B. Blake Warfarin is an anticoagulant used to to prevent heart attacks, strokes, and blood clots. Learn about side effects, interactions and indications. Can you tell me what I should

More information

Drug Class Review Newer Oral Anticoagulant Drugs

Drug Class Review Newer Oral Anticoagulant Drugs Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different

More information

Trends in Pneumonia and Influenza Morbidity and Mortality

Trends in Pneumonia and Influenza Morbidity and Mortality Trends in Pneumonia and Influenza Morbidity and Mortality American Lung Association Epidemiology and Statistics Unit Research and Health Education Division November 2015 Page intentionally left blank Introduction

More information

Link between effectiveness and cost data Costing was conducted prospectively on the same patient sample as that used in the effectiveness analysis.

Link between effectiveness and cost data Costing was conducted prospectively on the same patient sample as that used in the effectiveness analysis. Clinical and economic effectiveness of an inpatient anticoagulation service Mamdani M M, Racine E, McCreadie S, Zimmerman C, O'Sullivan T L, Jensen G, Ragatzki P, Stevenson J G Record Status This is a

More information

Disease Management. Measures At A Glance

Disease Management. Measures At A Glance s At A Glance Updated: 11/01/2018 URAC 2018 Page 1 of 7 Cross-Cutting Mandatory s (3) Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on

More information

Trends in Hospice Utilization

Trends in Hospice Utilization Proposed FY 2017 Hospice Wage Index and Rate Update and Hospice Quality Reporting Requirements To: NHPCO Provider Members From: Health Policy Team Date: April 25, 2016 On April 21, 2016, the Centers for

More information

Appendix G Explanation/Clarification Summary

Appendix G Explanation/Clarification Summary Appendix G Explanation/Clarification Summary Summary of Changes for Recommendations Alignment of measures with VBP by fiscal year Measures and service dates were adjusted to be consistent with the FY2016

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle   holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/188/20915 holds various files of this Leiden University dissertation. Author: Flinterman, Linda Elisabeth Title: Risk factors for a first and recurrent venous

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GYH. Assessment of the CHA 2 DS 2 -VASc score in predicting ischemic stroke, thromboembolism, and death

More information

2016 Physician Quality Reporting System Data Collection Form: Total Knee Replacement

2016 Physician Quality Reporting System Data Collection Form: Total Knee Replacement 2016 Physician Quality Reporting System Data Collection Form: Total Knee Replacement IMPORTANT: Any measure with a 0% performance rate (100% for inverse measures) is not considered satisfactory reporting.

More information

Is laparoscopic sleeve gastrectomy safer than laparoscopic gastric bypass?

Is laparoscopic sleeve gastrectomy safer than laparoscopic gastric bypass? Is laparoscopic sleeve gastrectomy safer than laparoscopic gastric bypass? A comparison of 30-day complications using the MBSAQIP data registry Sandhya B. Kumar MD, Barbara C. Hamilton MD, Soren Jonzzon,

More information

Appendix 1 (as supplied by the authors): Databases and definitions used.

Appendix 1 (as supplied by the authors): Databases and definitions used. Appendix 1 (as supplied by the authors): Databases and definitions used. Table e1: The Institute for Clinical Evaluative Sciences databases used in this study and their descriptions Database Ontario Health

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Pincus D, Ravi B, Wasserstein D. Association between wait time and 30-day mortality in adults undergoing hip fracture surgery. JAMA. doi: 10.1001/jama.2017.17606 eappendix

More information

Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a costeffectiveness

Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a costeffectiveness Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a costeffectiveness analysis Eckman M H, Singh S K, Erban J K, Kao G Record Status This is a critical abstract of an economic

More information

Performance Analysis:

Performance Analysis: Performance Analysis: Healthcare Utilization of CCNC- Population 2007-2010 Prepared by Treo Solutions JUNE 2012 Table of Contents SECTION ONE: EXECUTIVE SUMMARY 4-5 SECTION TWO: REPORT DETAILS 6 Inpatient

More information

Comparison of Medicare Fee-for-Service Beneficiaries Treated in Ambulatory Surgical Centers and Hospital Outpatient Departments

Comparison of Medicare Fee-for-Service Beneficiaries Treated in Ambulatory Surgical Centers and Hospital Outpatient Departments Comparison of Medicare Fee-for-Service Beneficiaries Treated in Ambulatory Surgical Centers and Hospital Outpatient Departments Prepared for: American Hospital Association April 4, 2019 Berna Demiralp,

More information

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARD FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Outcome Measures (Claims Based)

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARD FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Outcome Measures (Claims Based) Last Updated: Version 4.3 NQF-ENDORSED VOLUNTARY CONSENSUS STANDARD FOR HOSPITAL CARE Measure Information Form Collected For: CMS Outcome Measures (Claims Based) Measure Set: CMS Readmission Measures Set

More information

Proposed Expansion of the Patient Safety Indicator Set Patrick S. Romano, MD MPH UC Davis/USA

Proposed Expansion of the Patient Safety Indicator Set Patrick S. Romano, MD MPH UC Davis/USA Proposed Expansion of the Patient Safety Indicator Set Patrick S. Romano, MD MPH UC Davis/USA OECD Health Care Quality Indicators Patient Safety Subgroup 9 May 2012 AHRQ PSIs endorsed by OECD (after review

More information

*Corresponding Author:

*Corresponding Author: Audit of venous thromboembolism prophylaxis administered to general surgical patients undergoing elective and emergency operations at National Hospital, Sri Lanka *Migara Seneviratne 1, Asanka Hemachandra

More information

Presenter Disclosure Information

Presenter Disclosure Information Presenter Disclosure Information Soko Setoguchi, MD DrPH Prescription Drug Data: Advantages, Availability, and Access FINANCIAL DISCLOSURE: Grants/Research Support: NIH, AHRQ UNLABELED/UNAPPROVED USES

More information

Connecticut Joint Replacement Institute (CJRI) Outcomes Report

Connecticut Joint Replacement Institute (CJRI) Outcomes Report Connecticut Joint Replacement Institute () Outcomes Report Our Highlights: Nationally recognized Over 27,000 surgeries performed Devoted to excellence in patient care Proven superior outcomes that matter.

More information

Chapter 8: Cardiovascular Disease in Patients with ESRD

Chapter 8: Cardiovascular Disease in Patients with ESRD Chapter 8: Cardiovascular Disease in Patients with ESRD Cardiovascular disease (CVD) is common in adult end-stage renal disease (ESRD) patients, with coronary artery disease (CAD) and heart failure (HF)

More information

Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin Among Patients with Sickle Cell Disease: A Retrospective Cohort Study

Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin Among Patients with Sickle Cell Disease: A Retrospective Cohort Study Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin Among Patients with Sickle Cell Disease: A Retrospective Cohort Study Megan Roberts, PharmD, BCPS MUSC Medical Center and South Carolina

More information

CLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016

CLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016 CLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016 WHAT IS AN EPISODE OF CARE? An episode of care is a grouping of a patient s health care claims for a unique

More information

PEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)

PEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL) PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)

More information

Chapter 4: Cardiovascular Disease in Patients with CKD

Chapter 4: Cardiovascular Disease in Patients with CKD Chapter 4: Cardiovascular Disease in Patients with CKD The prevalence of cardiovascular disease (CVD) was 65.8% among patients aged 66 and older who had chronic kidney disease (CKD), compared to 31.9%

More information

DALLA REAL LIFE INTERNAZIONALE A QUELLA ITALIANA: ESPERIENZE DAL CAMPO

DALLA REAL LIFE INTERNAZIONALE A QUELLA ITALIANA: ESPERIENZE DAL CAMPO RIVAROXABAN DALLA REAL LIFE INTERNAZIONALE A QUELLA ITALIANA: ESPERIENZE DAL CAMPO Giuseppe Camporese, MD Azienda Ospedaliera Universitaria di Padova Dipartimento di Scienze Cardiache, Toraciche e Vascolari

More information

Objectives. Medicare Spending per Beneficiary: Analyzing MSPB Data to Identify Primary Drivers

Objectives. Medicare Spending per Beneficiary: Analyzing MSPB Data to Identify Primary Drivers Medicare Spending per Beneficiary: Analyzing MSPB Data to Identify Primary Drivers August 22, 2017 Objectives Understand the basics of the hospital specific MSPB data files and reports Review the factors

More information

2014 Evidence-Based HTN Guideline: Preliminary Data from AMGA s Anceta Collaborative

2014 Evidence-Based HTN Guideline: Preliminary Data from AMGA s Anceta Collaborative 2014 Evidence-Based HTN Guideline: Preliminary Data from AMGA s Anceta Collaborative February 2014 Patient Population Measure spec for MU/PD generally follows NQF 0018 (used for HEDIS, PQRS, and MU) 1.6

More information

4. Which survey program does your facility use to get your program designated by the state?

4. Which survey program does your facility use to get your program designated by the state? TRAUMA SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and

More information

Chapter 9: Cardiovascular Disease in Patients With ESRD

Chapter 9: Cardiovascular Disease in Patients With ESRD Chapter 9: Cardiovascular Disease in Patients With ESRD Cardiovascular disease is common in adult ESRD patients, with atherosclerotic heart disease and congestive heart failure being the most common conditions

More information

Measure Applications Partnership. Hospital Workgroup In-Person Meeting Follow- Up Call

Measure Applications Partnership. Hospital Workgroup In-Person Meeting Follow- Up Call Measure Applications Partnership Hospital Workgroup In-Person Meeting Follow- Up Call December 21, 2016 Feedback on Current Measure Sets for IQR, HACs, Readmissions, and VBP 2 Previously Identified Crosscutting

More information

Standing Posture at Work Does Not Increase the Risk of Varicose Veins among Health Care Providers in Taiwan

Standing Posture at Work Does Not Increase the Risk of Varicose Veins among Health Care Providers in Taiwan Original Paper Received: July 20, 2016 Accepted: February 28, 2017 Published online: February 28, 2017 Standing Posture at Work Does Not Increase the Risk of Varicose Veins among Health Care Providers

More information

Behavioral Health Hospital and Emergency Department Health Services Utilization

Behavioral Health Hospital and Emergency Department Health Services Utilization Behavioral Health Hospital and Emergency Department Health Services Utilization Rhode Island Fee-For-Service Medicaid Recipients Calendar Year 2000 Prepared for: Prepared by: Medicaid Research and Evaluation

More information

Pharmacy Prior Authorization

Pharmacy Prior Authorization Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Anticoagulant Injectable (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review

More information

Dr. Steve Ligertwood Dr. Roderick Tukker Dr. David Wilton

Dr. Steve Ligertwood Dr. Roderick Tukker Dr. David Wilton Dr. Steve Ligertwood Hospitalist Royal Columbian Hospital Regional Department Head-Hospitalist for Fraser Health Authority Project Lead BC Hospitalist VTE Collaborative Clinical Instructor, UBC School

More information

Chapter 2: Identification and Care of Patients With CKD

Chapter 2: Identification and Care of Patients With CKD Chapter 2: Identification and Care of Patients With Over half of patients from the Medicare 5% sample (restricted to age 65 and older) have a diagnosis of chronic kidney disease (), cardiovascular disease,

More information

Background. Correlation between epilepsy and attention deficit hyperactivity disorder. Background. Epidemiology of ADHD among children with epilepsy

Background. Correlation between epilepsy and attention deficit hyperactivity disorder. Background. Epidemiology of ADHD among children with epilepsy Correlation between epilepsy and attention deficit hyperactivity disorder I-Ching Chou M.D. Director, Department of Pediatric Neurology China Medical University Hospital Taiwan Background Attention deficit/hyperactivity

More information

Possible Denominator Codes Applicable to OMS * Le Fort Fractures 21346, 21347, 21348, 21422, 21423, 21432, 21433, 21435, 21436

Possible Denominator Codes Applicable to OMS * Le Fort Fractures 21346, 21347, 21348, 21422, 21423, 21432, 21433, 21435, 21436 2015 Individual PQRS s Eligible OMS #22: Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non- Cardiac Procedures) Percentage of noncardiac surgical patients aged 18 years and older undergoing

More information

Understanding Hierarchical Condition Categories (HCC)

Understanding Hierarchical Condition Categories (HCC) Understanding Hierarchical Condition Categories (HCC) How hierarchical condition category coding will impact your practice and how you can use these codes to increase quality, improve the patient experience,

More information

The Cost Burden of Worsening Heart Failure in the Medicare Fee For Service Population: An Actuarial Analysis

The Cost Burden of Worsening Heart Failure in the Medicare Fee For Service Population: An Actuarial Analysis Client Report Milliman Client Report The Cost Burden of Worsening Heart Failure in the Medicare Fee For Service Population: An Actuarial Analysis Prepared by Kathryn Fitch, RN, MEd Principal and Healthcare

More information

Status Update on the National Cardiovascular Prevention Guidelines - JNC 8, ATP 4, and Obesity 2

Status Update on the National Cardiovascular Prevention Guidelines - JNC 8, ATP 4, and Obesity 2 TABLE OF CONTENTS Status Update on the National Cardiovascular Prevention Guidelines 1 Drosperinone-Containing Oral Contraceptives and Venous Thromboembolism Risk 1-4 P&T Committee Formulary Action 5 Status

More information

PedCath IMPACT User s Guide

PedCath IMPACT User s Guide PedCath IMPACT User s Guide Contents Overview... 3 IMPACT Overview... 3 PedCath IMPACT Registry Module... 3 More on Work Flow... 4 Case Complete Checkoff... 4 PedCath Cath Report/IMPACT Shared Data...

More information

Tools to manage the introduction of new drugs in Italy: administrative databases, registries and risk-sharing sharing schemes.

Tools to manage the introduction of new drugs in Italy: administrative databases, registries and risk-sharing sharing schemes. Tools to manage the introduction of new drugs in Italy: administrative databases, registries and risk-sharing sharing schemes. Roberta Joppi - Italian Horizon Scanning Project Local Health Unit of Verona

More information

Top Ten Reasons For Failure To Prevent Postoperative Thrombosis

Top Ten Reasons For Failure To Prevent Postoperative Thrombosis Top Ten Reasons For Failure To Prevent Postoperative Thrombosis Joseph A. Caprini, MD, MS, FACS, RVT, FACCWS Louis W. Biegler Chair of Surgery NorthShore University HealthSystem, Evanston, IL Clinical

More information

Chapter 2: Identification and Care of Patients With CKD

Chapter 2: Identification and Care of Patients With CKD Chapter 2: Identification and Care of Patients With CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease

More information

WHI Extension Appendix A, Form 33D Medical History Update (Detail) (Ver. 9) Page 1

WHI Extension Appendix A, Form 33D Medical History Update (Detail) (Ver. 9) Page 1 WHI Extension Appendix A, Form 33D Medical History Update (Detail) (Ver. 9) Page 1 FORM: 33D - MEDICAL HISTORY UPDATE (Detail) Version: 9 March 30, 2007 Description: When used: Self-administered or interviewer-administered;

More information

An Increased Risk of Reversible Dementia May Occur After Zolpidem Derivative Use in the Elderly Population

An Increased Risk of Reversible Dementia May Occur After Zolpidem Derivative Use in the Elderly Population An Increased Risk of Reversible Dementia May Occur After Zolpidem Derivative Use in the Elderly Population A Population-Based Case-Control Study Hsin-I Shih, Che-Chen Lin, Yi-Fang Tu, Chia-Ming Chang,

More information

Chapter 2: Identification and Care of Patients with CKD

Chapter 2: Identification and Care of Patients with CKD Chapter 2: Identification and Care of Patients with CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease

More information

Partial Hospitalization Program Program for Evaluating Payment Patterns Electronic Report. User s Guide Sixth Edition. Prepared by

Partial Hospitalization Program Program for Evaluating Payment Patterns Electronic Report. User s Guide Sixth Edition. Prepared by Partial Hospitalization Program Program for Evaluating Payment Patterns Electronic Report User s Guide Sixth Edition Prepared by Partial Hospitalization Program Program for Evaluating Payment Patterns

More information

Is Hospital Admission Useful for Syncope Patients? Preliminary Results of a Multicenter Cohort

Is Hospital Admission Useful for Syncope Patients? Preliminary Results of a Multicenter Cohort Is Hospital Admission Useful for Syncope Patients? Preliminary Results of a Multicenter Cohort F. Dipaola, E. Pivetta, G. Costantino, G. Casazza, M.J. Reed, B. Sun, M. Solbiati, F. Barbic, D. Shiffer,

More information

Cost-Motivated Treatment Changes in Commercial Claims:

Cost-Motivated Treatment Changes in Commercial Claims: Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non- Medical Switching August 2017 THE MORAN COMPANY 1 Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non-Medical

More information

Data Fusion: Integrating patientreported survey data and EHR data for health outcomes research

Data Fusion: Integrating patientreported survey data and EHR data for health outcomes research Data Fusion: Integrating patientreported survey data and EHR data for health outcomes research Lulu K. Lee, PhD Director, Health Outcomes Research Our Development Journey Research Goals Data Sources and

More information